Edesa Biotech, Inc. (EDSA)
NASDAQ: EDSA · Real-Time Price · USD
2.430
-0.070 (-2.80%)
At close: Feb 21, 2025, 4:00 PM
2.314
-0.116 (-4.79%)
After-hours: Feb 21, 2025, 5:27 PM EST
Edesa Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
16.86M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
EDSA News
- 8 days ago - Edesa Biotech Reports Fiscal 1st Quarter 2025 Results - GlobeNewsWire
- 10 days ago - Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Edesa Biotech Reports Fiscal Year 2024 Results - GlobeNewsWire
- 4 months ago - Edesa Biotech's Founder Makes Strategic Investment in the Company - GlobeNewsWire
- 4 months ago - Edesa Biotech Announces Upcoming Conference Schedule - GlobeNewsWire
- 5 months ago - Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. - GlobeNewsWire
- 7 months ago - Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results - GlobeNewsWire
- 8 months ago - BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS - Accesswire